Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Tuebingen
• Treatments: Antibodies; Antibodies, Bispecific; Immunoglobulins

Criteria

Inclusion Criteria:

• malignant melanoma stage III/IV

• injectable soft tissue metastasis

• informed consent given

• Karnofsky >= 70%

Exclusion Criteria:

• additional chemotherapeutical treatment

• systemic glucocorticoids

• brain metestasis

• other malignancies